Long term follow up in all patients who received SAR422459 in previous study TDU13583
Phase 2Active 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stargardt's Disease
Conditions
Stargardt's Disease
Trial Timeline
Dec 14, 2012 → Aug 29, 2033
NCT ID
NCT01736592About Long term follow up in all patients who received SAR422459 in previous study TDU13583
Long term follow up in all patients who received SAR422459 in previous study TDU13583 is a phase 2 stage product being developed by Sanofi for Stargardt's Disease. The current trial status is active. This product is registered under clinical trial identifier NCT01736592. Target conditions include Stargardt's Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01736592 | Phase 2 | Active |
Competing Products
6 competing products in Stargardt's Disease